Boston Scientific Corp.
Here’s whether Boston Scientific Corp. (BSX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-6.42% over 10 days); RSI 11 — oversold; weak 1-year return of -52.4%; 3-month momentum negative (-32.8%). Currently 57.2% off its 52-week high. Score: -7/7.
BSX is trading below its 200-day MA ($82.40) — a key warning sign the longer-term trend is under pressure. An RSI of 11.3 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -52.4% compares to +22.9% for SPY (trailed the market by 75.3%). The current 57.2% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.